- Home
- ACRE vs CDXS Comparison
ACRE vs CDXS Comparison
Compare ACRE & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- CDXS
- Stock Information
- Founded
- ACRE 2011
- CDXS 2002
- Country
- ACRE United States
- CDXS United States
- Employees
- ACRE N/A
- CDXS N/A
- Industry
- ACRE Real Estate Investment Trusts
- CDXS Major Chemicals
- Sector
- ACRE Real Estate
- CDXS Industrials
- Exchange
- ACRE Nasdaq
- CDXS Nasdaq
- Market Cap
- ACRE 270.6M
- CDXS 201.3M
- IPO Year
- ACRE 2012
- CDXS 2010
- Fundamental
- Price
- ACRE $4.90
- CDXS $2.78
- Analyst Decision
- ACRE Hold
- CDXS Buy
- Analyst Count
- ACRE 7
- CDXS 2
- Target Price
- ACRE $5.50
- CDXS $11.00
- AVG Volume (30 Days)
- ACRE 470.3K
- CDXS 880.2K
- Earning Date
- ACRE 08-05-2025
- CDXS 08-07-2025
- Dividend Yield
- ACRE 12.15%
- CDXS N/A
- EPS Growth
- ACRE N/A
- CDXS N/A
- EPS
- ACRE N/A
- CDXS N/A
- Revenue
- ACRE $67,129,000.00
- CDXS $49,815,000.00
- Revenue This Year
- ACRE N/A
- CDXS $12.77
- Revenue Next Year
- ACRE N/A
- CDXS $22.12
- P/E Ratio
- ACRE N/A
- CDXS N/A
- Revenue Growth
- ACRE 83.51
- CDXS N/A
- 52 Week Low
- ACRE $3.35
- CDXS $1.90
- 52 Week High
- ACRE $7.99
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- ACRE 56.53
- CDXS 64.41
- Support Level
- ACRE $4.69
- CDXS $2.32
- Resistance Level
- ACRE $5.04
- CDXS $2.58
- Average True Range (ATR)
- ACRE 0.15
- CDXS 0.17
- MACD
- ACRE -0.02
- CDXS 0.05
- Stochastic Oscillator
- ACRE 62.50
- CDXS 81.08
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.